M. Dowler

发表

Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites.

Patricia De la Vega, S. Hoffman, J. Sacci, 2002, The Journal of infectious diseases.

Long-term efficacy and immune responses following immunization with the RTS,S malaria vaccine.

G. Wortmann, Joe D. Cohen, R. Wirtz, 1998, The Journal of infectious diseases.

Preerythrocytic, live-attenuatedPlasmodium falciparumvaccine candidates by design

A. Aly, S. Kappe, A. Cowman, 2009 .

Efficacy of recombinant circumsporozoite protein vaccine regimens against experimental Plasmodium falciparum malaria.

J. Palensky, J. Wittes, C. Ockenhouse, 2001, The Journal of infectious diseases.

IMRAS—A clinical trial of mosquito-bite immunization with live, radiation-attenuated P. falciparum sporozoites: Impact of immunization parameters on protective efficacy and generation of a repository of immunologic reagents

S. Chaudhury, T. Richie, L. Garver, 2020, PloS one.

Phase 1/2a Study of the Malaria Vaccine Candidate Apical Membrane Antigen-1 (AMA-1) Administered in Adjuvant System AS01B or AS02A

V. A. Stewart, S. D. de Vlas, Joe D. Cohen, 2009, PloS one.

Mosquito bisection as a variable in estimates of PCR-derived malaria sporozoite rates

R. Wilkerson, D. Foley, L. M. Rueda, 2012, Malaria Journal.

Parallel cascade analysis of Phycomyces light-growth response

E. Lipson, M. Dowler, J. Guo, 1995, Proceedings of 17th International Conference of the Engineering in Medicine and Biology Society.

Using infective mosquitoes to challenge monkeys with Plasmodium knowlesi in malaria vaccine studies

Cristina Stoyanov, M. Fay, R. Gwadz, 2014, Malaria Journal.

Mosquito bisection as a variable in estimates of PCR-derived malaria sporozoite rates

R. Wilkerson, D. Foley, L. M. Rueda, 2012, Malaria Journal.

ELECTROPHORETIC VARIANTS OF α-GLYCEROPHOSPHATE DEHYDROGENASE IN THE FIRE ANT SOLENOPSIS INVICTA

S. Vinson, M. Dowler, A. C. Hung, 1979 .

Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection.

V. A. Stewart, W. Ballou, Joe D. Cohen, 2009, The Journal of infectious diseases.

Preerythrocytic, live-attenuated Plasmodium falciparum vaccine candidates by design

A. Aly, S. Kappe, A. Cowman, 2009, Proceedings of the National Academy of Sciences.

Causal prophylactic efficacy of atovaquone-proguanil (Malarone) in a human challenge model.

K. Kain, J. Berman, K. Kester, 2001, Transactions of the Royal Society of Tropical Medicine and Hygiene.

Phase 2a trial of 0, 1, and 3 month and 0, 7, and 28 day immunization schedules of malaria vaccine RTS,S/AS02 in malaria-naïve adults at the Walter Reed Army Institute of Research.

M. Demoitié, W. Ballou, Joe D. Cohen, 2008, Vaccine.

A phase I/IIa safety, immunogenicity, and efficacy bridging randomized study of a two-dose regimen of liquid and lyophilized formulations of the candidate malaria vaccine RTS,S/AS02A in malaria-naïve adults.

Marie-Claude Dubois, Janet Wittes, J. Wittes, 2007, Vaccine.

Controlled Human Malaria Infection at the Walter Reed Army Institute of Research: The Past, Present, and Future From an Entomological Perspective.

L. Garver, M. Dowler, S. Davidson, 2015, U.S. Army Medical Department journal.

First-in-human evaluation of genetically attenuated Plasmodium falciparum sporozoites administered by bite of Anopheles mosquitoes to adult volunteers.

S. Kappe, A. Cowman, P. de la Vega, 2013, Vaccine.

Recombinant Liver Stage Antigen-1 (LSA-1) formulated with AS01 or AS02 is safe, elicits high titer antibody and induces IFN-gamma/IL-2 CD4+ T cells but does not protect against experimental Plasmodium falciparum infection.

V. A. Stewart, Marie-Claude Dubois, In-Kyu Yoon, 2010, Vaccine.